Review Reports
- Mayra Xochitl Durán-Maldonado 1,
- Ximena Hernández-Ramos 1 and
- Jesús Campos-García 1,*
- et al.
Reviewer 1: Anonymous Reviewer 2: Anonymous
Round 1
Reviewer 1 Report (Previous Reviewer 1)
Comments and Suggestions for AuthorsThe revised manuscript provided by the authors is greatly improved compared to the original submission. This author commends them for this effort, as a lot was asked of them. The authors have addressed all but one minor concern of this reviewer. Minor changes are suggested.
- For Figure 1a, line 119-120, I think the authors meant to say “10% of the wound area was closed” based on the graphed data and the image, or maybe “90% unclosed.” Currently, they say “10% unclosed” which would mean the wound is almost gone, but the data shown do not indicate that the statement is accurate.
- This reviewer still doesn’t understand the use of lower-case letters for statistics. The figure legend only says the letters represent p<0.05. However, what does “a” mean in the controls (there cannot be a significant difference for a control)? Does a=control, b mean p<0.05 while c means p<0.01 etc? Additional explanation is needed.
- The histology and its interpretation are vastly improved in the revision. The authors’ resubmission letter states a pathologist (or someone experienced with histology) helped with these experiments, but a new pathologist is not recognized among the author list, methods, and/or acknowledgements. The authors are encouraged to acknowledge the work of their colleague in the revision.
Author Response
Reviewer 1: Comments and Suggestions for Authors
The revised manuscript provided by the authors is greatly improved compared to the original submission. This author commends them for this effort, as a lot was asked of them. The authors have addressed all but one minor concern of this reviewer. Minor changes are suggested.
- For Figure 1a, line 118-120, I think the authors meant to say “10% of the wound area was closed” based on the graphed data and the image, or maybe “90% unclosed.” Currently, they say “10% unclosed” which would mean the wound is almost gone, but the data shown do not indicate that the statement is accurate.
Response 1:
We thank the reviewer for pointing out this ambiguity. The text has been revised to clearly state that approximately 90% of the wound area remained unclosed after 48 hours following CDPs treatment, which accurately represents the quantitative data and representative images shown in Figure 1a. (lines 113-119).
- This reviewer still doesn’t understand the use of lower-case letters for statistics. The figure legend only says the letters represent p<0.05. However, what does “a” mean in the controls (there cannot be a significant difference for a control)? Does a=control, b mean p<0.05 while c means p<0.01 etc? Additional explanation is needed.
Response 2:
We appreciate the reviewer for highlighting the need for further clarification on the statistical notation. The lowercase letters do not represent different p-value thresholds (e.g., p < 0.05 versus p < 0.01), nor do they signify specific experimental conditions such as control or treatment. Instead, these letters denote statistically similar groups identified by Tukey’s multiple comparison post hoc test after one-way ANOVA. Groups sharing the same letter are not significantly different from each other, whereas groups with different letters differ significantly at least with p < 0.05. The control group is included in these multiple comparisons and is assigned a letter based on its statistical relationship with the other experimental groups.
We have revised the figure legends to clearly clarify this point and prevent any possible misinterpretation.
- The histology and its interpretation are vastly improved in the revision. The authors’ resubmission letter states a pathologist (or someone experienced with histology) helped with these experiments, but a new pathologist is not recognized among the author list, methods, and/or acknowledgements. The authors are encouraged to acknowledge the work of their colleague in the revision.
Response 3:
We thank the reviewer for recognizing the importance of the pathologist who helped us interpret the histology slides. We also acknowledge her in the acknowledgments section.
Reviewer 2 Report (Previous Reviewer 2)
Comments and Suggestions for AuthorsThis manuscript investigates the anti-metastatic effects and potential mechanisms of bacterial cyclodipeptides (CDPs) in a triple-negative breast cancer (TNBC) model. The authors utilized the MDA-MB-231 cell line and an immunosuppressed mouse xenograft model to evaluate the inhibitory effects of CDPs on cancer cell migration, invasion, as well as in vivo tumor growth and metastasis. The study found that CDPs significantly reduced metastatic foci in lung and liver tissues by inhibiting the Akt/mTOR/S6K signaling pathway and downregulating the expression of key proteins such as Gab1, Vimentin, and FOXO1. Furthermore, combined treatment with CDPs and methotrexate (MTX) demonstrated a synergistic effect. This study provides valuable preclinical data for the development of CDPs as anti-tumor agents. However, the manuscript contains some shortcomings and requires further improvement.
Major Comments
- The authors need to provide more substantial experimental evidence to validate the proposed molecular mechanism. Although decreased phosphorylation levels of the Akt/mTOR/S6K pathway were observed, to establish causality, the authors should perform rescue or blocking experiments in in vitro studies using specific activators or inhibitors of this pathway (such as MK-2206 or Rapamycin). This is necessary to prove that the anti-metastatic effect of CDPs is indeed dependent on this signaling pathway rather than merely being a concomitant phenomenon. For the Western Blot data, the authors should provide quantitative analysis bar charts for all key proteins (e.g., p-Akt, t-Akt, p-mTOR, t-mTOR, etc.) and calculate the ratios of phosphorylated proteins to total proteins, rather than solely displaying band images, to enhance the statistical power of the data. In the in vivo experiment section, although the inhibition of tumor growth and metastasis is described, the authors should include more detailed animal safety assessment data. This includes H&E stained sections and detailed pathological scoring of major organs (heart, liver, spleen, lung, kidney), as well as the body weight change curves of the mice during the experiment, to comprehensively evaluate the systemic toxicity of CDPs.
- Regarding the assessment of metastatic foci, it is recommended that the authors adopt more precise quantification methods. For example, performing statistical analysis on the number and area of metastatic nodules in tissue sections, or utilizing bioluminescence imaging technology (if available) to track the metastatic process, would be more convincing than simple qualitative descriptions.
- To explore the molecular regulatory networks of breast cancer progression and the context of novel therapeutic strategies in depth, the authors should further expand the discussion section and place it within a broader research context. For instance, an in-depth discussion on the regulatory role of non-coding RNAs in breast cancer progression, as well as the application of novel delivery systems or therapeutic strategies in inhibiting postoperative metastasis, would greatly enrich the content of the article. Recent studies have revealed the critical role of MALAT1 in breast cancer progression (doi: 10.2174/0113892029305656240503045154); meanwhile, other studies have explored the potential of exosome-mediated siRNA delivery systems in suppressing postoperative breast cancer metastasis (doi: 10.1016/j.jconrel.2019.12.005). Comparing and integrating these cutting-edge findings with the mechanism of action of CDPs in this study would highlight the positioning and significance of this research within the field.
- In the description of statistical methods, the authors need to explicitly state whether post-hoc tests were conducted for comparisons between multiple groups, and ensure that the sample size selection has sufficient statistical power.
- The manuscript contains some grammatical errors and unidiomatic expressions in its language; professional native English editing is recommended to improve the readability and fluency of the article.
Author Response
Reviewer 2:
Comments and Suggestions for Authors
This manuscript investigates the anti-metastatic effects and potential mechanisms of bacterial cyclodipeptides (CDPs) in a triple-negative breast cancer (TNBC) model. The authors utilized the MDA-MB-231 cell line and an immunosuppressed mouse xenograft model to evaluate the inhibitory effects of CDPs on cancer cell migration, invasion, as well as in vivo tumor growth and metastasis. The study found that CDPs significantly reduced metastatic foci in lung and liver tissues by inhibiting the Akt/mTOR/S6K signaling pathway and downregulating the expression of key proteins such as Gab1, Vimentin, and FOXO1. Furthermore, combined treatment with CDPs and methotrexate (MTX) demonstrated a synergistic effect. This study provides valuable preclinical data for the development of CDPs as anti-tumor agents. However, the manuscript contains some shortcomings and requires further improvement.
Major Comments
- The authors need to provide more substantial experimental evidence to validate the proposed molecular mechanism. Although decreased phosphorylation levels of the Akt/mTOR/S6K pathway were observed, to establish causality, the authors should perform rescue or blocking experiments in in vitro studies using specific activators or inhibitors of this pathway (such as MK-2206 or Rapamycin). This is necessary to prove that the anti-metastatic effect of CDPs is indeed dependent on this signaling pathway rather than merely being a concomitant phenomenon.
Response 1:
We thank the reviewer for this insightful suggestion. We fully agree that rescue or blocking experiments using specific pharmacological modulators of the Akt/mTOR/S6K pathway (such as MK-2206 or rapamycin) are valuable approaches to determine direct causality in signaling studies. However, we respectfully believe that such experiments are not essential for the main conclusions of the presented findings.
First, the goal of this study was not to identify a single linear signaling pathway influenced by cyclodipeptides (CDPs), but rather to explore the anti-metastatic mechanism of bacterial CDPs as multitarget modulators acting on interconnected signaling networks. CDPs are not selective kinase inhibitors; instead, they have coordinated effects on multiple nodes related to tumor aggressiveness, including Akt/mTOR/S6K signaling, EMT markers (Vimentin, Gab1), immune-related genes, and metastatic spread in vivo.
Second, the mechanistic link between CDPs and Akt/mTOR inhibition has been previously demonstrated by our group using complementary pharmacological and molecular approaches in other cancer models (Apoptosis 25, 632–647 (2020). https://doi.org/10.1007/s10495-020-01619-z), where importantly, the bacterial CDPs treatment showed a similar effect to AZD8055 inhibitor on the p-mTOR-Ser2448 isoform, indicating that the molecular mechanism of CDPs involves mTOR inhibition, similar to the AZD8055 inhibitor. Additional results were also obtained with the LY294002 PI3K inhibitor, as the phosphorylation of the p-mTOR-Ser2448 isoform was affected by LY294002, but was completely abrogated when CDPs were added together with LY294002. Furthermore, LY294002 and AZD8055 inhibit the phosphorylation of Akt-Ser473 and consequently affect phosphorylation of PRAS40, TSC2, GSK3b, and FoxO1. These results indicate that the CDPs compete with target proteins of the AZD8055 and LY294002 inhibitors, confirming that the PI3K/Akt/mTOR/S6K pathway is targeted by the bacterial CDPs. These findings provide an established framework that the present study extends to metastatic TNBC.
Finally, although specific pathway blockade experiments could further clarify causality, they are beyond the scope of this current integrative in vitro-in vivo study and will be explored in future work specifically focused on pathway dissection.
- For the Western Blot data, the authors should provide quantitative analysis bar charts for all key proteins (e.g., p-Akt, t-Akt, p-mTOR, t-mTOR, etc.) and calculate the ratios of phosphorylated proteins to total proteins, rather than solely displaying band images, to enhance the statistical power of the data.
Response 2:
We thank the reviewer for this insightful suggestion. We fully agree; the figures showing phosphorylated and total protein forms in Western blot assays (Fig. 2 and 7) now display the ratios between them. Additionally, this description has been incorporated into the Results and Discussion sections.
- In the in vivo experiment section, although the inhibition of tumor growth and metastasis is described, the authors should include more detailed animal safety assessment data. This includes H&E stained sections and detailed pathological scoring of major organs (heart, liver, spleen, lung, kidney), as well as the body weight change curves of the mice during the experiment, to comprehensively evaluate the systemic toxicity of CDPs.
Response 3:
We thank the reviewer for highlighting the importance of systemic safety assessment in the in vivo experiments. We would like to clarify that animal safety was comprehensively evaluated in the present study.
Histopathological analyses using H&E staining were performed on major organs, including liver, lung, and spleen (Figure 8). These analyses did not reveal evidence of treatment-associated toxicity, such as tissue necrosis, inflammatory infiltration, hypertrophy, or architectural disruption in CDPs-treated animals. Instead, CDPs treatment preserved or restored normal tissue architecture compared with untreated TNBC mice.
In addition, body weight was monitored throughout the experimental period as an indicator of systemic toxicity, and no significant weight loss was observed in CDPs-treated animals compared with control groups (Figure S1).
We have now clarified these points in Discussion section to explicitly frame these analyses as part of the in vivo safety assessment of CDPs. (Lines 457-475).
- Regarding the assessment of metastatic foci, it is recommended that the authors adopt more precise quantification methods. For example, performing statistical analysis on the number and area of metastatic nodules in tissue sections, or utilizing bioluminescence imaging technology (if available) to track the metastatic process, would be more convincing than simple qualitative descriptions.
Response 4:
We thank the reviewer for this thoughtful and constructive suggestion. We fully agree that quantitative approaches, such as morphometric analysis of metastatic nodules or bioluminescence-based imaging, can offer a more precise assessment of metastatic burden. In the present study, metastatic dissemination was evaluated through multiple experimental methods, including (i) macroscopic examination of organs during necropsy, (ii) organ weight measurements, (iii) histopathological analysis of liver, lung, and spleen tissues, and (iv) molecular and biochemical markers related to metastasis and systemic tumor burden. As shown in Figure 4, untreated TNBC-bearing mice displayed increased organ weights and visible metastatic foci, whereas groups treated with CDPs showed normalized organ weights and no visible metastatic lesions. These results were reinforced by histological preservation of tissue architecture (Figure 8), normalization of serum biomarkers (AST and LDH), and gene expression analyses indicating coordinated changes in pathways linked to metastasis, immune evasion, and DNA damage response. We acknowledge that formal quantitative histomorphometric analysis of metastatic nodules (including number and area) was not performed in this study. The main goal of the in vivo experiments was to assess the therapeutic effects of CDPs on tumor growth, invasiveness, and metastasis at an advanced stage, integrating functional, histological, biochemical, and molecular data rather than focusing on a single quantitative measure. Regarding bioluminescence imaging, we recognize its high sensitivity and usefulness for continuous monitoring of metastatic spread; however, this technology was not available at the time the experiments were conducted.
- To explore the molecular regulatory networks of breast cancer progression and the context of novel therapeutic strategies in depth, the authors should further expand the discussion section and place it within a broader research context. For instance, an in-depth discussion on the regulatory role of non-coding RNAs in breast cancer progression, as well as the application of novel delivery systems or therapeutic strategies in inhibiting postoperative metastasis, would greatly enrich the content of the article. Recent studies have revealed the critical role of MALAT1 in breast cancer progression (doi: 10.2174/0113892029305656240503045154); meanwhile, other studies have explored the potential of exosome-mediated siRNA delivery systems in suppressing postoperative breast cancer metastasis (doi: 10.1016/j.jconrel.2019.12.005). Comparing and integrating these cutting-edge findings with the mechanism of action of CDPs in this study would highlight the positioning and significance of this research within the field.
Response 5:
We thank the reviewer for this valuable comment. In response, we expanded the Discussion section (lines 433-447) to place our findings in a broader molecular and therapeutic context. We included a focused discussion on the role of non-coding RNAs (ncRNAs) in breast cancer progression and metastasis, highlighting MALAT1 as a metastasis-associated lncRNA that plays an important role in regulating the PI3K/Akt/mTOR/FOXO1 axis and shows functional convergence with the signaling pathways inhibited by CDPs in our study.
Additionally, we discussed emerging ncRNA-based therapeutic strategies, including exosome-mediated siRNA delivery systems reported to suppress breast cancer metastasis in preclinical models. By comparing these approaches with our findings, we suggest the CDPs as molecules capable of influencing ncRNA-regulated signaling pathways without the need for complex delivery systems.
- In the description of statistical methods, the authors need to explicitly state whether post-hoc tests were conducted for comparisons between multiple groups, and ensure that the sample size selection has sufficient statistical power.
Response 6:
We appreciate the reviewer’s important comment regarding the statistical analysis and apologize for the lack of clarity in the original version. All quantitative data in this study were analyzed using one-way analysis of variance (ANOVA) when comparing more than two experimental groups, followed by post-hoc multiple comparison tests to identify statistically significant differences between groups. Specifically, Tukey’s post hoc test was used for pairwise comparisons after ANOVA, as now clearly stated in the revised Materials and Methods section and figure legends.
Regarding sample size, the number of biological replicates used in each experiment (n=3 for in vitro assays and n=5 animals per group for in vivo studies) aligns with standard practices in preclinical cancer research and animal xenograft models. These sample sizes were adequate to identify significant differences between groups with acceptable variability, as demonstrated by the clear separation of means and consistent statistical significance across independent assays.
To improve transparency, we clarified the statistical methodology, specifically mentioning the use of post-hoc tests and the reasons for sample sizes in the revised manuscript.
- The manuscript contains some grammatical errors and unidiomatic expressions in its language; professional native English editing is recommended to improve the readability and fluency of the article.
Response 7:
The manuscript was carefully revised to enhance its clarity and readability as suggested.
Round 2
Reviewer 2 Report (Previous Reviewer 2)
Comments and Suggestions for AuthorsThe authors have satisfactorily addressed the previous queries. This version of manuscript is acceptable for the journal.
This manuscript is a resubmission of an earlier submission. The following is a list of the peer review reports and author responses from that submission.
Round 1
Reviewer 1 Report
Comments and Suggestions for AuthorsDurán-Maldonado and team present their work investigating the therapeutic potential of bacteria-derived cyclodipeptides (CDPs) against triple negative breast cancer, specifically MDA-MB-231 cells in culture and in xenograft models. Their work suggests that CDPs inhibit invasion/metastasis and induce cancer cell death. The work is a nice combination of classical assays and both in vitro and in vivo testing. However, a major limitation is that there are concerns with the interpretation of some of the histology. It is strongly encouraged (required?) that the team consult a medical pathologist for interpretation of H&E images, as this reviewer believes some data is misinterpreted. There are also a few instances of missing controls that are concerning. Specific comments include:
Major concerns:
- Figure 1A: Poor image quality. Cannot tell the difference between neighboring cells and wounds. Due to different wound starting sizes, calculating the relative percent of wound remaining (typically used) accounts for this difference and should be used instead of raw values.
- In Figures 3 and 4 only the data for TNBC + CDP treatment is shown for procedure 1. The controls are not graphed for a comparison. Either (1) the entire set of controls needs to be shown for procedure 1 in a separate graph, or (2) only procedure 2 should be shown. The authors can choose which option. Also using (1) and (2) would be much less confusing to the reader rather than (i) and (m) since it is unknown why (i) and (m) were chosen for the designations.
- In Figure 5, the authors describe “fat droplets” within the tumor tissues, but this may be adipocytes with tumor invasion around the adipocytes while CDP treated tumors may be less invasive and earlier stage and, therefore, have fewer adipocytes within the dense tumor tissue. Also, liver H&E in Figure 5 looks abnormal for CDP treatment. It is suggested that the investigators evaluate the tissue for signs of hepatitis or other pathological conditions like fibrosis. This is especially important given that methotrexate has been linked to liver fibrosis. Overall, the methods do not indicate that a trained pathologist has evaluated the tissue to confirm the authors’ interpretations and a pathologist’s interpretation will greatly strengthen the data in this figure.
- Figure 7 shows bone histology. Given that the peripheral blood indicates increased leukocyte counts, hematopoiesis may be disrupted, contributing to differences in bone histology. Immunohistochemical staining, or another detection method, for a basal subtype epithelial marker, such as cytokeratin 14, is needed to validate tumor cell metastasis in the bone. This is particularly important since MDA-MB-231 cells have low metastasis rates to the bone (leading to the creation of sublines that are more metastatic to distinct tissues PMID: 18424382). Control bone H&E is missing. It is unlikely that tumor cells would appear as pink clusters without hematoxylin-stained nuclei, which should be prominent. These clusters of pink cells may be regions of erythropoiesis, since these hallmarks can be seen in normal mouse bone marrow (another reason why control bone marrow H&E is needed in this figure). Again, a trained medical pathologist should evaluate the histology.
- Methods: The culturing conditions for MCF7 cells is a concern, as it does not follow ATCC guidelines and, from personal experience, MCF7 cells do not grow well without insulin. There is a concern that the MCF7 cells have undergone a selective pressure and may not behave the same as MCF7 cells properly cultured. Also note, that MCF7 is not a triple negative breast cancer line, so it’s inclusion in this study is unjustified. A second TNBC line would have been more appropriate for scientific rigor. Also, the orthotopic injection model is not a typical location for orthotopic xenograft studies – usually the inguinal glands are used and a “blind” injection (without opening the skin and verifying fat pad as the site of injection, or doing an intraductal injection) is not a typical approach since it could accidentally be an intradermal injection instead. The authors should take note of this issue for future work. Also, the supplier (and catalog number) for each primary antibody should be added.
Minor concerns and text edits:
- Lines 104-107 have a duplicate sentence.
- Statistics: The results of statistical tests are presented as lower case letters on the graphs, but there is no description of what the threshold p value is for each letter. This is complicated by the fact that the authors sometimes use asterisks (*) instead of letters. Samples size is n=3, but it is not described whether it is technical or biological replicates.
- The Discussion reads more like a summary of the results. The authors are encouraged to add more context about their work within the existing literature and to identify potential weaknesses or areas for future study.
Reviewer 2 Report
Comments and Suggestions for AuthorsThis manuscript explores the inhibitory effects of bacterial cyclic dipeptides (CDPs) used alone and in combination with methotrexate (MTX) on triple-negative breast cancer metastasis. The authors validated through in vitro cell experiments and in vivo mouse models that CDPs exert anti-metastatic effects by regulating the Akt/mTOR/S6K pathway and metastasis-related markers including Gab1, Vimentin, and FOXO1. This study provides a new strategic direction for triple-negative breast cancer treatment; however, the manuscript still requires improvement in the following aspects:
Major Comments
- The authors should provide a more comprehensive review of the tumor microenvironment's impact on triple-negative breast cancer metastasis, particularly the role of microorganisms within the tumor microenvironment. The heterogeneity of intratumoral microbial communities and their relationship with tumor development has become an important research area. The authors could cite relevant studies to supplement the theoretical foundation (PMID: 40463500, doi: 10.1002/mdr2.70006, 10.1002/imt2.70070).
- Although the authors examined key proteins in the Akt/mTOR/S6K pathway, the mechanistic analysis of how CDPs specifically regulate these molecular targets remains insufficiently detailed. The authors should supplement protein-protein interaction network analysis and explore the effects of CDPs on cell cycle checkpoints and DNA damage repair mechanisms. Research on the mechanisms of immune checkpoints in cancer therapy could provide insights for this work (PMID: 40463500, doi: 10.1002/mdr2.70019).
- In the xenograft mouse model, the authors should supplement additional safety evaluation indicators, including comprehensive testing of biochemical markers such as liver and kidney function and cardiac enzyme profiles. Pharmacokinetic studies are also needed to assess the distribution, metabolism, and clearance of CDPs in vivo.
- The authors should discuss the feasibility and challenges of translating these research findings to clinical applications, including aspects such as CDP manufacturing processes, quality control, and optimization of administration routes. Experience with nanomaterial applications in tumor therapy could provide reference for CDP delivery system design (10.1002/imm3.70007).
- The authors are recommended to employ multi-omics approaches such as transcriptomics and proteomics to comprehensively analyze the mechanisms of action of CDPs. The application of bioinformatics tools such as gene set enrichment analysis will help deepen understanding of CDP regulation of cellular signaling pathways (10.1002/mdr2.70000, 10.1002/mdr2.70001).
- The authors could combine current trends in cancer diagnosis and treatment to discuss the potential application value of CDPs in precision medicine. The application of multi-omics technologies in biomedical research provides new insights for disease prediction and treatment strategy optimization (doi: 10.1016/j.cpan.2024.12.002; 10.1016/j.cpan.2024.12.001).
Minor Comments
- The article requires professional native language editing to reduce grammatical errors and some non-idiomatic expressions.
- The abstract section needs to be rewritten to more concisely summarize the main content and clinical significance of the article.